• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Precigen Stock Turns Heads After Q3 Profit Swing

    Simply Wall St·11/08/2026 13:38:19
    Listen to the news
    • Precigen reported third quarter 2026 revenue of US$74.15 million and net income of US$35.77 million, compared with much smaller revenue and a sizeable loss in the same period a year earlier, with basic earnings per share from continuing operations at US$0.10.
    • The shift from a substantial loss to profit for both the quarter and the first nine months of 2026 gives investors a fresh data point on how Precigen’s operating model and cost base respond when the pipeline begins to generate material revenue.
    • We will look at how Precigen's sharp swing to quarterly profitability may reshape the investment narrative built around PAPZIMEOS driven expectations.

    Compare Precigen's sharp move into profitability with a curated set of other high quality stocks using our 19 high quality undiscovered gems that may not yet be fully on the market's radar.

    Precigen Investment Narrative Recap

    To own Precigen, you need to believe PAPZIMEOS can support a real commercial business, not just a one quarter earnings spike. The Q3 move to US$35.77 million of net income and US$0.10 basic EPS shows what the model looks like when revenue of US$74.15 million lands on the current cost base.

    The near term catalyst is continued PAPZIMEOS pull through in adult RRP, supported by payer coverage and manufacturing execution. The biggest risk stays the same. Precigen is highly exposed to one indication, so any slowdown in uptake, reimbursement friction, or emerging safety or durability concerns could quickly pressure margins and delay cash flow breakeven ambitions.

    The most relevant update is the Q3 and nine month 2026 earnings release on 4 November. It puts hard numbers behind the PAPZIMEOS thesis, with year to date revenue of US$152.38 million and net income of US$47.91 million. The shift from a sizeable loss a year ago to profit gives you a clearer view of operating leverage.

    That said, the stock still trades on a P/E that is well above the US biotech sector average. As a result, a lot of that story is already priced in. Your call is whether this level of profitability is repeatable as real world use expands, or whether high fixed costs, pricing pressure, or slower than expected patient onboarding start to bite into what Q3 just showed.

    Precigen's analyst narrative projects US$654.3 million in revenue and US$393.8 million in earnings by 2029, based on assumed yearly revenue growth of 96.9% and an earnings change of roughly US$730.5 million from current earnings of a US$336.7 million loss.

    Uncover why Precigen's fair value indicates a 205% potential upside to its current price, which could narrow quickly.

    NasdaqGS:PGEN 1-Year Stock Price Chart
    NasdaqGS:PGEN 1-Year Stock Price Chart

    Exploring Other Perspectives

    One alternate view leans on platform diversification at Precigen rather than just PAPZIMEOS. The most optimistic analysts were already penciling in about US$621.6 million in revenue and US$374.0 million in earnings by 2029, supported by broader AdenoVerse success. You can treat Q3 2026 as fresh input and then compare several competing narratives before deciding which appears more realistic.

    Explore 2 other Precigen fair value estimates, including one that suggests as much as 916% upside from the current price!

    Decide For Yourself

    Don't just follow the ticker; dig into the data and build a conviction that's truly your own.

    Looking For More Investment Ideas Beyond Precigen?

    If Precigen has sharpened your focus on quality and risk, it can be useful to compare it with other stocks that fit very different checklists. Use the Simply Wall St Screener to line up several options side by side and see which businesses better match your return goals, time horizon, and comfort with volatility.

    • If you want income to play a bigger role in your portfolio, scan for companies described as 7 dividend fortresses to see which payouts align with your risk tolerance.
    • If capital preservation matters most, start with companies that appear in our 31 resilient stocks with low risk scores and benchmark their risk profile against what you see with Precigen.
    • If you are hunting for quality at a potentially appealing price, compare Precigen with the 38 high quality undervalued stocks and weigh the fundamentals side by side.